Literature DB >> 2985411

Kinetics and displacement of [11C]RO 15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography.

Y Samson, P Hantraye, J C Baron, F Soussaline, D Comar, M Mazière.   

Abstract

The brain regional distribution and kinetics of RO 15-1788, a benzodiazepine (BZD) antagonist labeled with 11C was studied by time-of-flight positron tomography after intravenous injection in four normal human volunteers. In two control studies, there was a high uptake of [11C]RO 15-1788 in gray matter structures initially (brain/blood ratio approximately 3), and subsequent retention that was highest in cerebral cortex, a structure known to have a high density of BZD receptors in vitro. Variation in tissue kinetics of [11C]RO among different gray matter structures may, however, suggest regional differences in binding characteristics or environment of BZD receptors. In two displacement studies, unlabeled RO 15-1788 was injected ten minutes after the radioligand: there was an immediate and marked washout of [11C]brain radioactivity that reached 70% in the occipital cortex with a 0.05 mg/kg dose (indicating a high specific to non-specific binding ratio) but was less prominent with a 0.01 mg/kg dose. These data suggest that [11C]RO 15-1788 may be useful for in vivo mapping of human brain BZD receptors using positron tomography.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985411     DOI: 10.1016/0014-2999(85)90218-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  26 in total

1.  [11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. Preparation, autoradiography and positron emission tomography.

Authors:  C Halldin; L Farde; J E Litton; H Hall; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).

Authors:  L L Ponto; J A Ponto
Journal:  Clin Pharmacokinet       Date:  1992-04       Impact factor: 6.447

Review 3.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

Review 4.  Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  Synthesis and evaluation of 11C-PK 11195 for in vivo study of peripheral-type benzodiazepine receptors using positron emission tomography.

Authors:  K Hashimoto; O Inoue; K Suzuki; T Yamasaki; M Kojima
Journal:  Ann Nucl Med       Date:  1989-07       Impact factor: 2.668

Review 6.  Pharmacology of the benzodiazepine receptor.

Authors:  W E Haefely
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

7.  A quantitative cerebral and whole body autoradiographic study of a intravenously administered benzodiazepine antagonist 3H-Ro 15-1788 in mice.

Authors:  R d'Argy; A Persson; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

8.  Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography.

Authors:  H Shinotoh; M Iyo; T Yamada; O Inoue; K Suzuki; T Itoh; H Fukuda; T Yamasaki; Y Tateno; K Hirayama
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 9.  Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.

Authors:  Stina Syvänen; Jonas Eriksson
Journal:  ACS Chem Neurosci       Date:  2012-12-04       Impact factor: 4.418

10.  11C-labeled 2'-iododiazepam for PET studies of benzodiazepine receptors: synthesis and comparison of biodistribution with its radioiodinated compound.

Authors:  Y Iida; H Saji; Y Magata; J Konishi; I Nakatsuka; A Yoshitake; A Yokoyama
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.